Este sitio web utiliza cookies para poder ofrecerle una mejor experiencia de usuario. La información de las cookies se almacena en su navegador y ejecuta funciones, como reconocerlo cuando regresa a nuestro sitio y ayudar a nuestro equipo a entender qué secciones son más interesantes y útiles para usted.
9 abril, 2020 by Moeller IP Brazil, Coronavirus (COVID-19), INPI Brazil, Patent, Pharmaceutical Products 0 comments
INPI Brazil | On COVID-19 Priority Examination for Pharmaceutical Products and Processes
The Official Bulletin 2570 from April 07, 2020, published the right to request priority examination for pharmaceutical products and processes and equipment and/or materials for use in health for the diagnosis, prophylaxis, and treatment of Covid-19.
The transcript of the Resolution issued follows below:
Art. 1 BRPTO Resolution No. 239, from June 4, 2019, published in RPI No. 2528, July 18, 2019, becomes effective with the following changes:
«Art. 12-A. The patent process in which one the object is related to pharmaceutical products and processes and equipment and/or materials for use in health for the diagnosis, prophylaxis and treatment of Covid-19 will have priority in the processing.
- 1 The request for priority processing must be filed until June 30, 2021, by the applicant, attorney or interested third party, individual or legal entity, and must contain a clarification indicating the relationship of the matter of the process with the diagnosis, prophylaxis of the population and/or treatment of patients at Covid-19.
- 2 The Directorate of Patents, Computer Programs and Topographies of Integrated Circuits (DIRPA) may regulate the submission and examination process and even temporarily suspend, in whole or in part according to the effectiveness of the service provision, the receipt of requests of the caput of the article for patent processes.